DK0808162T3 - Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt - Google Patents

Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt

Info

Publication number
DK0808162T3
DK0808162T3 DK96902984T DK96902984T DK0808162T3 DK 0808162 T3 DK0808162 T3 DK 0808162T3 DK 96902984 T DK96902984 T DK 96902984T DK 96902984 T DK96902984 T DK 96902984T DK 0808162 T3 DK0808162 T3 DK 0808162T3
Authority
DK
Denmark
Prior art keywords
heart failure
congestive heart
carbazole compounds
treat congestive
carvedilol
Prior art date
Application number
DK96902984T
Other languages
Danish (da)
English (en)
Inventor
Gisbert Sponer
Klaus Strein
Mary Ann Lukas-Laskey
Robert Ruffolo Jr
Neil Shusterman
Original Assignee
Boehringer Mannheim Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26012210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0808162(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1995103995 external-priority patent/DE19503995C2/de
Application filed by Boehringer Mannheim Pharm Corp filed Critical Boehringer Mannheim Pharm Corp
Application granted granted Critical
Publication of DK0808162T3 publication Critical patent/DK0808162T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK96902984T 1995-02-08 1996-02-07 Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt DK0808162T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1995103995 DE19503995C2 (de) 1995-02-08 1995-02-08 Verwendung von Carvedilol zur Verminderung der Mortalität bei Patienten mit eingeschränkter myocardialer Funktion
US08/483,635 US5760069A (en) 1995-02-08 1995-06-07 Method of treatment for decreasing mortality resulting from congestive heart failure
PCT/EP1996/000498 WO1996024348A2 (fr) 1995-02-08 1996-02-07 Utilisation de composes de carbazole pour le traitement de l'insuffisance cardiaque congestive

Publications (1)

Publication Number Publication Date
DK0808162T3 true DK0808162T3 (da) 1999-11-15

Family

ID=26012210

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96902984T DK0808162T3 (da) 1995-02-08 1996-02-07 Anvendelse af carbazolforbindelser til behandling af kongestiv hjertesvigt

Country Status (26)

Country Link
US (6) US5760069A (fr)
EP (1) EP0808162B1 (fr)
JP (1) JP3546058B2 (fr)
KR (1) KR100295940B1 (fr)
CN (1) CN1093760C (fr)
AT (1) ATE179891T1 (fr)
AU (1) AU702106C (fr)
BR (1) BR9607111A (fr)
CA (1) CA2212548C (fr)
CZ (1) CZ292002B6 (fr)
DE (1) DE69602424T2 (fr)
DK (1) DK0808162T3 (fr)
ES (1) ES2134588T3 (fr)
FI (1) FI973255A7 (fr)
GR (1) GR3030966T3 (fr)
HU (1) HUP9900773A3 (fr)
NO (1) NO314830B1 (fr)
NZ (1) NZ301692A (fr)
PL (1) PL321737A1 (fr)
RO (1) RO121629B1 (fr)
RU (1) RU2197242C2 (fr)
SI (1) SI0808162T1 (fr)
SK (1) SK106897A3 (fr)
UA (1) UA55382C2 (fr)
WO (1) WO1996024348A2 (fr)
ZA (1) ZA96994B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
WO1998015272A1 (fr) * 1996-10-09 1998-04-16 BOEHRINGER MANNHEIM PHARMACEUTICALS CORP. - SMITHKLINE BEECHAM CORPORATION, LIMITED PARTNERSHIP No.1 Procede d'inhibition de proteines kinases activees par contrainte
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
CN1285738A (zh) * 1997-11-12 2001-02-28 泊灵格曼海姆药品公司及史密斯克莱恩贝克曼公司 卡维地洛的新的口服剂型
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
WO2001017528A1 (fr) * 1999-09-08 2001-03-15 Nitromed, Inc. Methodes de traitement et de prevention de l'insuffisance cardiaque au moyen de composes d'hydralazine et de dinitrate d'isosorbide ou de mononitrate d'isosorbide
US7537785B2 (en) * 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
EP1244455B1 (fr) * 1999-10-29 2009-07-22 Nitromed, Inc. Methodes de traitement de maladies vasculaires caracterisees par une insuffisance du monoxyde d'azote
US7235237B2 (en) * 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
IL153688A0 (en) 2000-06-28 2003-07-06 Teva Pharma Carvedilol
US20050009897A1 (en) * 2001-04-02 2005-01-13 Karen Anderson Method of treatment
WO2003028718A1 (fr) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Nouvelles formulations de carvedilol
JP2005504815A (ja) * 2001-10-02 2005-02-17 スミスクライン・ビーチャム・コーポレイション カルベジロールの新規組成物
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
SE0103749D0 (sv) * 2001-11-08 2001-11-08 Sahltech Ab Treatment of congestive heart failure
PL371409A1 (en) * 2002-01-15 2005-06-13 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
RU2203063C1 (ru) * 2002-03-12 2003-04-27 Нестерук Владимир Викторович Способ получения твердой лекарственной формы препарата, обладающего диуретическим действием
JP2006500320A (ja) * 2002-04-30 2006-01-05 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール一クエン酸塩一水和物
AU2003302218A1 (en) * 2002-05-16 2004-06-18 Genelabs Technologies, Inc Aryl and heteroaryl compounds as antibacterial and antifungal agents
MXPA04012923A (es) * 2002-06-27 2005-03-31 Sb Pharmco Inc Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
AU2003251627A1 (en) * 2002-06-27 2004-01-19 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
ES2211846T3 (es) * 2002-07-25 2004-07-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Uso de cilobradina o sus sales farmaceuticamente aceptables para el tratamiento o la prevencion de la insuficiencia cardiaca.
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
WO2005051322A2 (fr) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Base libre de carvedilol, ses sels, formes anhydres ou solvates, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et procedes de traitement ou d'administration
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1778267A4 (fr) * 2004-07-16 2010-01-06 Nitromed Inc Compositions et methodes associees a l'insuffisance cardiaque
EP1781611A1 (fr) * 2005-06-09 2007-05-09 Teva Pharmaceutical Industries Ltd. Formes cristallines du carvedilol et leurs procedes de preparation
CA2634473A1 (fr) * 2006-02-17 2007-08-30 Nitromed, Inc. Procedes utilisant des composes d'hydralazine et du dinitrate d'isosorbide ou du mononitrate d'isosorbide
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US8703804B2 (en) * 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
AU2007254283A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
WO2008002683A2 (fr) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Carvédilol phosphate
US20080207726A1 (en) * 2007-02-26 2008-08-28 Santiago Ini Process for the purification of carvedilol or its salts thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
WO2009140659A2 (fr) 2008-05-16 2009-11-19 Corthera, Inc. Méthode de traitement de la dyspnée associée à une insuffisance cardiaque aiguë
AU2011240773C1 (en) 2010-04-12 2015-08-27 Supernus Pharmaceuticals Inc. Methods for producing viloxazine salts and novel polymorphs thereof
AR089646A1 (es) 2011-08-12 2014-09-10 Boehringer Ingelheim Vetmed Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos
EP3468539A4 (fr) * 2016-06-13 2020-01-15 Ascendia Pharmaceuticals, LLC Administration à libération prolongée par voie parentérale de systèmes de dispersion de carvédilol
US10772869B1 (en) 2019-07-24 2020-09-15 ECI Pharmaceuticals, LLC Pharmaceutical compositions including carvedilol and methods of using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
SE460945B (sv) * 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
RU2058144C1 (ru) * 1988-12-15 1996-04-20 Центр по химии лекарственных средств Средство для лечения сердечной недостаточности
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5225401A (en) * 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
RU2032685C1 (ru) * 1991-12-16 1995-04-10 Центр по химии лекарственных средств Производные пиридо (3,2-а)карбазола, обладающие кардиотонической активностью
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure

Also Published As

Publication number Publication date
AU702106B2 (en) 1999-02-11
KR19980702085A (ko) 1998-07-15
JPH10513463A (ja) 1998-12-22
GR3030966T3 (en) 1999-11-30
CA2212548A1 (fr) 1996-08-15
RO121629B1 (ro) 2008-01-30
JP3546058B2 (ja) 2004-07-21
HK1014861A1 (en) 1999-10-08
BR9607111A (pt) 1997-11-04
MX9706042A (es) 1998-06-30
CZ292002B6 (cs) 2003-07-16
KR100295940B1 (ko) 2001-08-07
PL321737A1 (en) 1997-12-22
US5760069A (en) 1998-06-02
WO1996024348A3 (fr) 1996-10-03
WO1996024348A2 (fr) 1996-08-15
EP0808162A2 (fr) 1997-11-26
HUP9900773A2 (hu) 1999-07-28
NO973667L (no) 1997-08-08
CZ246397A3 (cs) 1998-11-11
AU4718196A (en) 1996-08-27
UA55382C2 (uk) 2003-04-15
DE69602424D1 (de) 1999-06-17
SI0808162T1 (en) 1999-10-31
CN1093760C (zh) 2002-11-06
AU702106C (en) 2005-02-17
USRE40707E1 (en) 2009-05-05
RU2197242C2 (ru) 2003-01-27
USRE40000E1 (en) 2008-01-08
HUP9900773A3 (en) 2000-04-28
US20010044455A1 (en) 2001-11-22
EP0808162B1 (fr) 1999-05-12
ATE179891T1 (de) 1999-05-15
ZA96994B (en) 1997-10-27
NO314830B1 (no) 2003-06-02
US20030105138A1 (en) 2003-06-05
FI973255A0 (fi) 1997-08-07
FI973255A7 (fi) 1997-08-07
US5902821A (en) 1999-05-11
DE69602424T2 (de) 1999-10-07
SK106897A3 (en) 1999-03-12
NZ301692A (en) 2000-09-29
CN1185106A (zh) 1998-06-17
NO973667D0 (no) 1997-08-08
CA2212548C (fr) 1999-08-24
ES2134588T3 (es) 1999-10-01

Similar Documents

Publication Publication Date Title
FI973255A0 (fi) Karbatsoliyhdisteiden käyttö verentungosta aiheuttavan sydämen toiminnanvajauksen hoidossa
NO20013727D0 (no) Anvendelse av Botulinumtoksin B for fremstilling av et medikament
DK0869808T3 (da) Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation
ES2150663T3 (es) Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
AU2001272666A1 (en) 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
PT998287E (pt) Utilizacao de levobupivacaina
HUP9904360A2 (hu) Eljárás emesis és központi idegrendszeri rendellenességek kezelésére, optikailag tiszta (+)-norciszaprid alkalmazásával
DE60322102D1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
ES2101073T3 (es) Nuevos aza-androstano-derivados 17-beta-substituidos.
NO964348L (no) CCK- eller gastrin-modulerende 5-hetrocykliske-1,5-benzodiazepiner
EA199800866A1 (ru) Способ снятия боли
DE69227583D1 (de) Arylmorpholine, herstellung und verwendung
EE9700231A (et) Aminotetraliini derivaat kardiovaskulaarsete haiguste raviks
ATE293972T1 (de) Behandlung von chronischen schmerzen
NZ299006A (en) Use of 4-dichlorophenyl tetrahydro N-methyl-1-naphthalenamine (sertraline) for heart attack treatment
NO20024545D0 (no) Fremgangsmåte for behandling av kongestiv hjertefeil
HUP9801925A1 (hu) Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
DE69428797D1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
DE69909097D1 (de) 5-bicycloindolverbindungen
FR2416890A1 (fr) Derives de 1,5-benzothiazepines, leur preparation et leurs utilisations therapeutiques
ATE74505T1 (de) Schmerzpraeparat.
PL365040A1 (en) Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure
UA36762A (uk) Спосіб лікування хворих на обмежену склеродермію
OA09519A (fr) D-acide aspartique b-hydroxamate en tant que medicament